Solstice Bio Nets Series A Venture Capital
Monday, January 07, 2013 5:38:00 AM PDT | VentureDeal
San Francisco, California -- Solstice Biologics (no website) has secured $18 million in its first round of venture capital investment.
Solstice is developing RNAi-based cell permeable drugs in the field of nucleic acid therapeutics.
VenBio led the round, which also included Aeris Capital AG.
The company did not disclose how the funding proceeds would be used.
Email Page | Print Page